Publications by authors named "Christopher Nunes Gomes"
High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is part of the treatment strategy for some patients with high-risk lymphoma by improving survival with an acceptable toxicity profile. Although the BEAM (BCNU, etoposide, cytarabine, and melphalan) intensification regimen is the most used, the optimal dosing for each drug is unclear. Here, we retrospectively compared the outcome of 110 patients receiving higher (400 mg/m, n = 69) or lower (200 mg/m, n = 41) etoposide and cytarabine doses in our institution between 2012 and 2019.
View Article and Find Full Text PDFArticle Synopsis
- * Researchers analyzed 91 patients and found multiple gene mutations, with FLT3 and NPM1 being the most common; specific mutations were linked to remission success, treatment resistance, and post-relapse mortality.
- * Short-term outcomes were best predicted by general health and performance status, while long-term outcomes were better assessed using genomic classifications, highlighting the need for tailored prognostic systems for older patients, as existing models primarily focus on younger individuals.
Progressive multifocal leukoencephalopathy (PML) is a fatal demyelinating disease of the central nervous system resulting from the reactivation of the John Cunningham virus (JCV). PML occurs almost exclusively during profound immune suppression but it can also be observed in immunocompromised subjects as part of an inflammatory immune reconstitution syndrome (IRIS) in patients receiving antiviral therapy. We report a case of PML in a 61-year-old patient with acute myeloid leukemia who had developed after discontinuation of durvalumab (anti-PD-L1) therapy initiated after multiple treatments.
View Article and Find Full Text PDFArticle Synopsis
- Immunoglobulin replacement therapy is often recommended for severe hypogammaglobulinemia in patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT), but its link to increased infection risk remains unconfirmed.
- A study involving 76 allo-HSCT patients found no significant difference in gamma globulin levels between those who had infections and those who did not during the first 100 days post-transplant.
- The findings suggest that humoral deficiency has a limited role in immune deficiency during this period, raising questions about the necessity of immunoglobulin replacement therapy.
Diffuse large B-cell lymphoma (DLBCL) with extra nodal skeletal involvement is rare. It is currently unclear whether these lymphomas should be treated in the same manner as those without skeletal involvement. We retrospectively analyzed the impact of combining high-dose methotrexate (HD-MTX) with an anthracycline-based regimen and rituximab as first-line treatment in a cohort of 93 patients with DLBCL and skeletal involvement with long follow-up.
View Article and Find Full Text PDFObjective: Interleukin-26 (IL-26) has a unique ability to activate innate immune cells due to its binding to circulating double-stranded DNA. High levels of IL-26 have been reported in patients with chronic inflammation. We aimed to investigate IL-26 levels in patients with systemic lupus erythematosus (SLE).
View Article and Find Full Text PDF